Avanos Medical, Inc.

AVNS trades at its 52-week peak with an extraordinarily elevated RSI of 82.4, signaling severe overbought conditions that historically precede pullbacks. The company's unprofitable status (P/E unavailable) combined with extreme momentum suggests the stock has detached from fundamental valuation anchors. With only 3.27% short interest, there's minimal squeeze dynamics to fuel further rallies, meaning the current move relies entirely on sustained buying pressure in a medical device name trading near historical highs. The risk-reward setup appears increasingly asymmetrical, with limited upside cushion relative to the vulnerability inherent in stretched technicals.